Microbiome Manufacturing Market Trends and Global Forecasts, 2035 - Close to 170 Trials are Evaluating Microbiome ...

DUBLIN, March 15, 2024 /PRNewswire/ -- The "Microbiome Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, till 2035: Distribution by Type of Product Manufactured, Type of Formulation, Type of Primary Packaging Used, Scale of Operation, Company Size, Key Geographical Regions and Leading Developers" report has been added to ResearchAndMarkets.com's offering.

The global microbiome manufacturing market size is estimated to grow from USD 27 million in 2023 to USD 187 million by 2035, representing a CAGR of 17% during the forecast period 2023-2035

The key objective of this market report is to provide a detailed market forecast analysis in order to estimate the existing microbiome manufacturing market size and future opportunity for microbiome manufacturers over the next decade. Based on several parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market evolution during the forecast period 2023-2035. 

The human body is known to harbor numerous communities of microbes, including both beneficial and harmful species, which are collectively referred to as microbiota. Likewise, the ecological system of commensal, symbiotic, and pathogenic microorganisms that reside within a host system is called the microbiome. Given the role of the microbiota in both disease development and pathogenesis, the concept of microbiome-based therapeutics has, over time, piqued the interest of the medical science community.

In fact, the last two decades have witnessed several developments in the field of microbiome therapy research and their therapeutic applications. Live biotherapeutic products (LBP), a class of microbiome therapy, involve the use of live microorganisms, such as bacteria, viruses, or fungi, to prevent or treat various disease conditions. LBPs are specifically designed for therapeutic purposes and are regulated as medicinal products or biologics in many countries.

These therapeutic modalities consist of well-characterized specific strains of microorganisms that are extensively researched for their intended medical applications, followed by rigorous testing and clinical trials to demonstrate safety and efficacy for treating or preventing specific medical condition. Further, the microbiome-based therapeutic approach has the potential to profile the microbiome composition of the patient using gene sequencing; this will lead to the development of tailored treatment options.

It is worth highlighting that in November 2022, the US Food and Drug Administration (FDA) approved the first microbiome-based therapy, RBX2660 (developed by Rebiotix) for the treatment of recurrent Clostridium difficile infection.

With the advancement of several promising microbiome-based live biotherapeutic products through clinical pipelines, this upcoming therapeutic segment is anticipated to become one of the fastest growing global market within the pharmaceutical industry in the coming years. Despite several developments in the field of microbiome-based therapies, and decades of experience growing bacteria to produce biologics, the biotech industry is still ill-equipped for microbiome manufacturing, including live biotherapeutic products manufacturing.

Manufacturing of live bacterial therapies at large scale is fraught with various challenges. Some of the key concerns of contemporary innovators include prolonged development timelines, stringent temperature control requirements, complex engineering of diverse aerobic / anaerobic strains (depending on the type of microbe) and inconsistencies related to quality attributes of the final product.

Therefore, outsourcing of microbiome therapeutics manufacturing to CMOs and CDMOs emerged as a lucrative option for human microbiome therapy developers to overcome the existing manufacturing issues. These CMOs and CDMOs (which are a part of the broader biologics contract manufacturing market) are increasingly focusing on enhancing their offerings by incorporating novel technologies in order to streamline microbiome manufacturing processes, increase production efficiency, and improve quality. This will further propel the microbiome market as well as the microbiome manufacturing market.

Microbiome Manufacturing Market Key Market Insights

The report features an extensive study of the current market landscape, market size and future opportunities for the microbiome manufacturing companies, including those involved in live biotherapeutic manufacturing, during the given forecast period. Further, this microbiome manufacturing market analysis highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the microbiome manufacturing market report are briefly discussed below.

Competitive Landscape of Microbiome Manufacturing Companies

The microbiome manufacturing market features a mix of large, mid-sized and small in-house players and contract manufacturing organizations that are engaged in the production of microbiome therapy across different scales of operations, such as preclinical, clinical, and commercial. Currently, 50% of the microbiome therapy contract manufacturers offer services for both API and FDF manufacturing; notable examples (in alphabetical order) include Arranta Bio, BacThera, Biose, Capsugel and Cerbios-Pharma. In addition, majority of the microbiome companies offer probiotic manufacturing services on a contract basis.

It is worth mentioning several microbiome-based products, including fecal microbiota transplantation (FMT) procedures, and dietary supplements, have been approved in the US; of which probiotics / prebiotics are the most commonly available formulations in the market as they do not require marketing approval from the regulatory agencies.

Notably, in April 2023, SER-109, a microbiome-based first oral therapy developed by Seres Therapeutics for the prevention of recurring Clostridium difficile infection, received marketing approval from the FDA. The growing demand for novel microbiome therapeutics, approvals from various regulatory bodies and technological advancements in order to streamline the manufacturing process, are expected to drive the microbiome manufacturing market growth during the forecast period.

Clinical Trials Analysis: Close to 170 Trials are Evaluating Microbiome Therapeutics to Treat Various Infectious Diseases and Oncological Disorders

Over the years, microbiome companies involved in the manufacturing of microbiome therapeutics have made significant efforts to conduct clinical trials for evaluating the efficacy of microbiome therapies targeting various disorders, including infectious diseases, neurological disorders and oncological disorders.

Close to 170 clinical trials have been conducted across different geographical regions to evaluate various microbiome therapies, of which, majority (70%) were registered in North America. Further, the maximum number of patients (10,138) were observed to be enrolled in clinical trials conducted in North America, which account for 52% of the overall enrollment. It is worth mentioning that AOBiome is conducting the maximum number of trials in this industry for different dermatological, respiratory and CNS disorders. In addition, VE303 (developed by Vedanta Biosciences) for the treatment of recurrent Clostridium difficile infection has demonstrated positive results in the Phase II clinical trials.

Market Trends Analysis: Partnerships and Collaborations have Fueled Microbiome Manufacturing Market Growth

Several stakeholders have been forging alliances with other industry / non-industry players in the microbiome therapeutics contract manufacturing industry. It is worth highlighting that since 2018, over 50 strategic partnerships have been established in this domain, of which the majority are focused on research, product development, and technology utilization.

In June 2023, Biose entered into a technology utilization agreement with SBT Instruments in order to integrate the latter company's technology into the former company's manufacturing process, with an aim to shorten the drug development timelines from clinical trials to market. Earlier, in April 2023, Microbiotica had signed an agreement with MSD to evaluate the clinical activity of its live biotherapeutic product, MB097, in combination with KEYTRUDA, MSD's anti-PD-1 therapy, in melanoma patients with primary resistance to an anti-PD-1-containing immunotherapy. This can be attributed to the incessant efforts of microbiome manufacturers to further advance the development of their product offerings, across different phases.

Microbiome Contract Manufacturing Companies' Capacity Utilization Rate is Expected to Increase Significantly in the Coming Years

Around 43% of the global microbiome contract manufacturing capacity is installed in facilities owned by small contract manufacturing companies. Further, majority share (57%) of the overall microbiome manufacturing capacity is installed in facilities located in Europe; within Europe, more than 35% of this capacity is installed in facilities owned by players based in Austria.

This can be attributed to the fact that majority of the manufacturing facility dedicated to the production of microbiome are located in Europe. It is worth mentioning that, over the past few years, the microbiome manufacturing capacity installed in Asia-Pacific and rest of the world has also increased at a commendable pace. This is primarily driven by the technical advances, low labor costs and socio-economic reforms favoring the growth of specialty industries, such as the microbiome industry.

Microbiome Manufacturing Market Size: Europe to Hold the Largest Market Share

The microbiome manufacturing market is estimated to be worth USD 27 million in 2023. Driven by the growing pipeline of microbiome-based products, the microbiome manufacturing market is anticipated to grow at a CAGR of 17% during the forecast period. Specifically, in terms of type of product manufactured, majority of the market share is anticipated to be captured by APIs by 2035. Further, the liquid dosage form continues to hold the largest share (50%) in the contract manufacturing industry.

Leading Contract Manufacturing Companies Engaged in Microbiome Manufacturing Market

Examples of key microbiome contract manufacturing companies (which have also been profiled in this report) offering manufacturing services include (in alphabetical order) Biose, BJP Laboratories, Capsugel, Cerbios-Pharma, Chr. Hansen, Inpac Probiotics, NIZO, WACKER and Winclove. In addition, MaaT Pharma is in the process of expanding its cGMP manufacturing capacity through the addition of a new plant in France that will exclusively focus on microbiome therapeutics manufacturing; the plant is set to be operational before the end of 2023. This market report includes an easily searchable excel database of all the microbiome contract manufacturing companies and their manufacturing facility, worldwide.

Scope of the Report

• Base Year: 2022
• Forecast Period: 2023-2035
• Market Size 2023: $27 Million
• CAGR: 17%
• Customization Scope: 15% Customization Available
• PowerPoint Presentation: (Complimentary)
• Type of Product Manufactured
• Type of Formulation
  • Solid
  • Liquid
  • Others
• Type of Primary Packaging Used
  • Blister Packs
  • Glass / Plastic Bottles
  • Pouches / Sachets
  • Vials
• Scale of Operation
  • Clinical
  • Commercial
• Company Size
  • Small
  • Mid-sized
  • Large and Very Large
• Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Leading Developers
  • Infant Bacterial Therapeutics
  • MaaT Pharma
  • Microbiomik Healthcare
  • OxThera
  • Rebiotix
  • Seres Therapeutics
• Key Companies Profiled
  • Biose
  • BJP Laboratories
  • Capsugel
  • Chr. Hansen
  • Inpac Probiotics
  • NIZO
  • WACKER
  • Winclove
  • (Full list of more than 60 companies captured is available in the report)
• Excel Data Packs: (Complimentary)
  • Market Landscape Analysis
  • Company Competitiveness Analysis
  • Likely Partner Analysis
  • Big Pharma Initiatives
  • Recent Developments and Initiatives
  • Clinical Trial Analysis
  • Capacity Analysis
  • Demand Analysis
  • Market Forecast and Opportunity Analysis

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry:

• Founder and Executive Chairman, Small Company, US
• Managing Director and Scientific Head, Large Company, India
• Managing Director and Chief Executive Officer, Mid-sized Company, India
• Co-Founder and Chief Executive Officer, Small Company, Belgium
• Founder and Chief Executive Officer, Small Company, US
• Chief Business Officer, Mid-sized Company, Israel
• Chief Operating Officer, Mid-sized Company, US
• Vice President, Business Development, Small Company, US
• Vice President, Commercial Operations, Mid-sized Company, US
• Vice President, Business Development, Mid-sized Company, US
• Vice President, Sales and Business Development, Small Company, US
• Head of Business Development, Mid-sized Company, Australia
• Business Development Manager, Large Company, Germany

For more information about this report visit https://www.researchandmarkets.com/r/yyfrmq

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and MarketsLaura Wood, Senior Manager[email protected]  For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets